New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment

© 2015, Sociedade Brasileira de Medicina Tropical. All rights reserved. Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for hum...

Descripción completa

Detalles Bibliográficos
Autores: Chávez-Fumagalli, Miguel A., Soto, Manuel, Ferraz Coelho, Eduardo Antonio
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2015
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/139947
Acceso en línea:http://hdl.handle.net/10261/139947
Access Level:acceso abierto
Palabra clave:Nanoparticles
Toxicity
Treatment
Lipid-based formulations
Amphotericin B
Leishmaniasis
id ES_4d997b67f5529cc18d0c76fb2cd969e8
oai_identifier_str oai:digital.csic.es:10261/139947
network_acronym_str ES
network_name_str España
repository_id_str
spelling New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatmentChávez-Fumagalli, Miguel A.Soto, ManuelFerraz Coelho, Eduardo AntonioNanoparticlesToxicityTreatmentLipid-based formulationsAmphotericin BLeishmaniasis© 2015, Sociedade Brasileira de Medicina Tropical. All rights reserved. Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio.Peer ReviewedSociedade Brasileira de Medicina TropicalConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]2016201620152016info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/139947reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésSíinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/1399472026-05-22T06:33:51Z
dc.title.none.fl_str_mv New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
title New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
spellingShingle New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
Chávez-Fumagalli, Miguel A.
Nanoparticles
Toxicity
Treatment
Lipid-based formulations
Amphotericin B
Leishmaniasis
title_short New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
title_full New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
title_fullStr New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
title_full_unstemmed New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
title_sort New delivery systems for amphotericin B applied to the improvement of leishmaniasis treatment
dc.creator.none.fl_str_mv Chávez-Fumagalli, Miguel A.
Soto, Manuel
Ferraz Coelho, Eduardo Antonio
author Chávez-Fumagalli, Miguel A.
author_facet Chávez-Fumagalli, Miguel A.
Soto, Manuel
Ferraz Coelho, Eduardo Antonio
author_role author
author2 Soto, Manuel
Ferraz Coelho, Eduardo Antonio
author2_role author
author
dc.contributor.none.fl_str_mv Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Nanoparticles
Toxicity
Treatment
Lipid-based formulations
Amphotericin B
Leishmaniasis
topic Nanoparticles
Toxicity
Treatment
Lipid-based formulations
Amphotericin B
Leishmaniasis
description © 2015, Sociedade Brasileira de Medicina Tropical. All rights reserved. Leishmaniasis is one of the six major tropical diseases targeted by the World Health Organization. It is a life-threatening disease of medical, social and economic importance in endemic areas. No vaccine is yet available for human use, and chemotherapy presents several problems. Pentavalent antimonials have been the drugs of choice to treat the disease for more than six decades; however, they exhibit high toxicity and are not indicated for children, for pregnant or breastfeeding women or for chronically ill patients. Amphotericin B (AmpB) is a second-line drug, and although it has been increasingly used to treat visceral leishmaniasis (VL), its clinical use has been hampered due to its high toxicity. This review focuses on the development and in vivo usage of new delivery systems for AmpB that aim to decrease its toxicity without altering its therapeutic efficacy. These new formulations, when adjusted with regard to their production costs, may be considered new drug delivery systems that promise to improve the treatment of leishmaniasis, by reducing the side effects and the number of doses while permitting a satisfactory cost-benefit ratio.
publishDate 2015
dc.date.none.fl_str_mv 2015
2016
2016
2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/139947
url http://hdl.handle.net/10261/139947
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Sociedade Brasileira de Medicina Tropical
publisher.none.fl_str_mv Sociedade Brasileira de Medicina Tropical
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407702347677697
score 15.812429

Similares en LA Referencia